Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?

What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey

(2023) Gillian R. Currie et al.   CLINICAL RHEUMATOLOGY

Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial

(2022) Joachim Gerss et al.   ANNALS OF THE RHEUMATIC DISEASES

Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study

(2022) Luiza R. Grazziotin et al.   Pediatric Rheumatology

Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis

(2022) Michelle M A Kip et al.   RHEUMATOLOGY

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

(2022) Karen B. Onel et al.   Arthritis & Rheumatology

Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors

(2022) Job Gieling et al.   Pediatric Rheumatology

Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study

(2021) Luiza R. Grazziotin et al.   Rheumatology and Therapy

Survey Fatigue During the COVID-19 Pandemic: An Analysis of Neurosurgery Survey Response Rates

(2021) Rosaline de Koning et al.   Frontiers in Surgery

Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible?

(2020) Inge R. Klein-Wieringa et al.   CURRENT OPINION IN RHEUMATOLOGY

Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system

(2020) Michelle M. A. Kip et al.   Expert Review of Pharmacoeconomics & Outcomes Research

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis

(2019) Sarah Ringold et al.   ARTHRITIS CARE & RESEARCH

Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature

(2019) Olha Halyabar et al.   PEDIATRIC DRUGS

Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration

(2018) Gabriele Simonini et al.   ARTHRITIS CARE & RESEARCH

Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance

(2017) Daniel B. Horton et al.   JOURNAL OF RHEUMATOLOGY

Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review

(2017) Rebecca Davies et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort

(2015) Jaime Guzman et al.   ANNALS OF THE RHEUMATIC DISEASES

Exploring physician specialist response rates to web-based surveys

(2015) Ceara Tess Cunningham et al.   BMC Medical Research Methodology

Shared decision making: Concepts, evidence, and practice

(2015) A.M. Stiggelbout et al.   PATIENT EDUCATION AND COUNSELING

Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis

(2012) C. M. A. LEBLANC et al.   JOURNAL OF RHEUMATOLOGY

The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis

(2011) Yu-Tsan Lin et al.   AUTOIMMUNITY REVIEWS